Literature DB >> 22441732

Cerebrospinal fluid cathepsin B and S.

Elin Nilsson1, Constantin Bodolea, Torsten Gordh, Anders Larsson.   

Abstract

Cathepsins are increased in the brain of elderly animals. We investigate the presence of cathepsin B and S in human cerebrospinal fluid (CSF) plasma and the associations with cystatin C, age and sex. We measured cathepsin B and S concentrations in CSFs from 118 persons, undergoing elective surgical procedures, with ELISA. Both cathepsin B and cathepsin S were positively correlated with age. No correlation was observed between cathepsin B or S and length, height or body mass index. Both cathepsin B and S were positively correlated to the cystatin C concentration in CSF. Calculated reference intervals were 4,893-17,636 pg/mL for cathepsin B and 2,681-11,459 pg/mL for cathepsin S. Elderly individuals had significantly higher levels of both cathepsin B (r s = 0.38, p = 0.00002) and cathepsin S (r s = 0.35, p = 0.0001) in CSF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441732     DOI: 10.1007/s10072-012-1022-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

1.  Cathepsin B-dependent motor neuron death after nerve injury in the adult mouse.

Authors:  Li Sun; Zhou Wu; Masashi Baba; Christoph Peters; Yasuo Uchiyama; Hiroshi Nakanishi
Journal:  Biochem Biophys Res Commun       Date:  2010-07-29       Impact factor: 3.575

2.  Determination of cerebrospinal fluid cystatin C on Architect ci8200.

Authors:  Annaby Moussa Ndjole; Constantin Bodolea; Tom Nilsen; Torsten Gordh; Mats Flodin; Anders Larsson
Journal:  J Immunol Methods       Date:  2010-06-21       Impact factor: 2.303

3.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C.

Authors:  S Coulibaly; H Schwihla; M Abrahamson; A Albini; C Cerni; J L Clark; K M Ng; N Katunuma; O Schlappack; J Glössl; L Mach
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

5.  The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study.

Authors:  C A Lemere; J S Munger; G P Shi; L Natkin; C Haass; H A Chapman; D J Selkoe
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  The liberation of fractalkine in the dorsal horn requires microglial cathepsin S.

Authors:  Anna K Clark; Ping K Yip; Marzia Malcangio
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

7.  The clinical significance of cathepsin S expression in human astrocytomas.

Authors:  Thomas Flannery; David Gibson; Menakshi Mirakhur; Stephen McQuaid; Caroline Greenan; Anne Trimble; Brian Walker; Derek McCormick; Patrick G Johnston
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

8.  Impairment of microglial responses to facial nerve axotomy in cathepsin S-deficient mice.

Authors:  Hai Peng Hao; Katsumi Doh-Ura; Hiroshi Nakanishi
Journal:  J Neurosci Res       Date:  2007-08-01       Impact factor: 4.164

9.  Role of the cysteine protease cathepsin S in neuropathic hyperalgesia.

Authors:  Jane Barclay; Anna K Clark; Pam Ganju; Clive Gentry; Sadhana Patel; Glen Wotherspoon; Frank Buxton; Chuanzheng Song; Jakir Ullah; Janet Winter; Alyson Fox; Stuart Bevan; Marzia Malcangio
Journal:  Pain       Date:  2007-01-23       Impact factor: 6.961

10.  Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain.

Authors:  Anna K Clark; Ping K Yip; John Grist; Clive Gentry; Amelia A Staniland; Fabien Marchand; Maliheh Dehvari; Glen Wotherspoon; Janet Winter; Jakir Ullah; Stuart Bevan; Marzia Malcangio
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-05       Impact factor: 11.205

View more
  5 in total

1.  Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.

Authors:  Georg Nübling; M Schuberth; K Feldmer; A Giese; L M Holdt; D Teupser; S Lorenzl
Journal:  Exp Brain Res       Date:  2017-05-10       Impact factor: 1.972

2.  Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.

Authors:  Yisel Cantres-Rosario; Marines Plaud-Valentín; Yamil Gerena; Richard L Skolasky; Valerie Wojna; Loyda M Meléndez
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

Review 3.  Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders.

Authors:  Gregory Hook; Thomas Reinheckel; Junjun Ni; Zhou Wu; Mark Kindy; Christoph Peters; Vivian Hook
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 4.  Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders.

Authors:  Vivian Hook; Michael Yoon; Charles Mosier; Gen Ito; Sonia Podvin; Brian P Head; Robert Rissman; Anthony J O'Donoghue; Gregory Hook
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-04-17       Impact factor: 3.036

Review 5.  Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate.

Authors:  Gregory Hook; J Steven Jacobsen; Kenneth Grabstein; Mark Kindy; Vivian Hook
Journal:  Front Neurol       Date:  2015-09-02       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.